To Evaluate the Efficacy and Safety of MaxioCel Versus Aquacel Extra for the Management of Chronic Wounds
Launched by AXIO BIOSOLUTIONS PVT. LTD. · Mar 28, 2022
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the effectiveness and safety of two different wound dressings, MaxioCel and Aquacel Extra, for treating chronic wounds that ooze, such as diabetic foot ulcers and venous or arterial ulcers. The study will last for 4 weeks, and researchers are looking to see which dressing helps wounds heal better.
To participate, you must be at least 18 years old and have a wound that has not healed for 1 to 24 months, with a size between 1 and 50 square centimeters. Unfortunately, if you have certain health conditions, allergies to the dressings, or are pregnant, you may not be eligible. If you join the study, you'll receive one of the two dressings and will be monitored throughout the trial to see how your wound responds to the treatment. This is a great opportunity for those with chronic wounds to potentially benefit from new treatment options.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female 18 years old or above (till 80 years)
- • Patients who are willing to sign the written informed consent
- • Clinically diagnosed with an unhealed or non-healing diabetic foot ulcer / venous ulcer / arterial ulcer / other ulcers / wounds, etc.
- • Wound duration between 1 to 24 months
- • A target wound area between 1 cm2 and 50 cm2
- • Exuding wounds / ulcers
- Exclusion Criteria:
- • Known allergy/hypersensitivity to the dressing
- • Pregnant women
- • Underlying or diagnosed with serious diseases or deemed unsuitable for this clinical study by the study's clinician
- • Dry wounds
- • Being treated with a high dose of steroids or immunosuppressant therapy or systemic antibiotics
- • Presenting a progressive neoplastic lesion treated with radiotherapy or chemotherapy
- • Patients who had Deep Vein Thrombosis in the previous 3 months
- • Ulcers with clinical signs of infection or erysipelas of the lower limb or biofilm
- • Subjects included in clinical study at present or during the past 30 days
- • Clinical suspicion of osteomyelitis
About Axio Biosolutions Pvt. Ltd.
Axio Biosolutions Pvt. Ltd. is a pioneering biotechnology company dedicated to advancing healthcare solutions through innovative medical technologies. Specializing in the development of advanced wound care products and biosurgical solutions, Axio aims to enhance patient outcomes and streamline clinical practices. With a commitment to rigorous research and development, the company leverages cutting-edge science to create effective, safe, and scalable healthcare products. Their focus on quality and efficacy positions Axio as a trusted partner in the clinical trial landscape, striving to meet the evolving needs of healthcare professionals and patients alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chennai, Tamil Nadu, India
Chennai, , India
Hyderabad, , India
Vijayawada, , India
Chennai, Tamilnadu, India
Patients applied
Trial Officials
Shailee Mehta, MSc
Study Chair
Axio Biosolutions Pvt. Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials